December 1, 2011
Dainippon Sumitomo Pharma (DSP) announced on November 30 that the company filed on November 18 a new drug application (NDA) for the fixed-dose combination DSP-8153 of the antihypertensive treatment Avapro (irbesartan), an angiotensin receptor blocker (ARB), and Amlodin (amlodipine), a...read more